MedPath
HSA Approval

BETNOVATE SCALP APPLICATION 0.1% w/w

SIN07714P

BETNOVATE SCALP APPLICATION 0.1% w/w

BETNOVATE SCALP APPLICATION 0.1% w/w

May 5, 1994

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Regulatory Information

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

Formulation Information

SOLUTION

**DOSAGE AND ADMINISTRATION** A small quantity of Betnovate Scalp Application should be applied to the scalp night and morning until improvement is noticeable. It may then be possible to sustain improvement by applying once a day, or less frequently.

TOPICAL

Medical Information

**INDICATIONS** Steroid responsive dermatoses of the scalp such as psoriasis, seborrhoea capitis, inflammation associated with severe dandruff.

**CONTRA-INDICATIONS** Infections of the scalp. Hypersensitivity to the preparation. Use is not indicated in dermatoses in children under one year of age, including dermatitis.

D07AC01

betamethasone

Manufacturer Information

GLAXOSMITHKLINE PTE LTD

ASPEN BAD OLDESLOE GMBH

Active Ingredients

BETAMETHASONE VALERATE EQV BETAMETHASONE

0.1% w/w

Betamethasone

Documents

Package Inserts

Betnovate Scalp Application PI.pdf

Approved: February 3, 2004

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BETNOVATE SCALP APPLICATION 0.1% w/w - HSA Approval | MedPath